Allergan To Pay $300M To End Birth Control Antitrust Case
Allergan said on Monday that it has agreed to pay several groups of Loestrin buyers a total of $300 million and will avoid a looming trial over claims that a pair...To view the full article, register now.
Already a subscriber? Click here to view full article